Aqemia

The company boasts its intricate level of accuracy within its physics algorithms that are fed into AI discovery, leading to a level of speed and in turn scaling drug discovery at an impressive rate. Creating a name for itself Aqemia moves away from using experimental data and bases the AI powered outcomes on years of data and studies of its now impressive team of 50.

Aqemia’s discoveries have already made an impact in oncology and immuno-oncology trials. The company sets goals to be part of more life changing clinical trials with wholly or partly owned drug candidates and continues to scale its platform to continue wins in its research. It will be exciting to see how more research and collaborations like that with Servier (international pharmaceutical company) will continue to grow its success.